Hu’s team is fast-tracking the development of the potential vaccine, with trials possibly beginning in May.
“It’s rewarding to know that our product can help expedite the search for a COVID-19 vaccine,” TriAltus CEO Bob Shufflebarger said.
The CL7 technology was invented by a team led by Dr. Dmitry Vassylyev, TriAltus co-founder and professor of biochemistry and molecular biology at The University of Alabama at Birmingham (UAB).
TARGETING A TREATMENT
In Huntsville, a collaboration aims to learn how the human immune system responds to the SARS-CoV-2 virus, which causes COVID-19, with hopes for developing an effective treatment for the disease.
“The most effective way to stop pandemics is with vaccines,” said Dr. Rick Myers, president and scientific director for HudsonAlpha. “However, the pipeline for vaccine production from development, to testing, to market can take years. A COVID-19 treatment is the best way to bridge the gap until a vaccine is widely available.”
Researchers at HudsonAlpha and iRepertoire hope the results of the study can be used to find and test possible treatments or cures for COVID-19 by using antibodies identified in patients diagnosed with COVID-19.
“The immune system is nature’s best doctor,” said Dr. Jian Han, founder and chief scientific officer of iRepertoire. “By understanding the immune system of patients that have effectively fought the pathogen, we can pinpoint the exact identity of cells that effectively eliminate the virus out of millions of possibilities.”
Involved in this battle on many fronts, UAB reported that it has raised more than $1.1 million for clinical and basic research focused on the novel coronavirus and COVID-19.
The money was dedicated to clinical research and basic research projects proposed by UAB faculty in the School of Medicine. Fifty-two proposals were submitted, with 14 basic science projects selected for funding, with help from UAB’s Hugh Kaul Precision Medicine Institute.
“Because of the urgency of this pandemic, one of the criteria was how quickly the research team could launch their study, and how quickly they could begin to see results,” said Dr. Etty (Tika) Benveniste, senior vice dean for Basic Sciences at UAB.
“We wanted research studies that could be reviewed at the three- and six-month time frames to determine their potential. That is a very accelerated timeline for research.”
UAB is also participating in a global clinical trial of potential COVID-19 treatments, including remdesivir, which has received emergency FDA approval as a therapeutic agent against the virus.
In addition, UAB and Birmingham’s Southern Research are collaborating with Scripps Research to test drugs that could be effective against COVID-19.